Inferensys

Service

Clinical AI Model Validation and Auditing

Independent, rigorous validation and performance auditing of clinical AI models against real-world datasets to ensure safety, efficacy, and fairness before deployment, supporting regulatory submissions and internal governance.
Governance lead reviewing model governance framework on laptop, policy documents visible, executive office setup.

Independent, rigorous validation of clinical AI models to ensure safety, efficacy, and fairness for regulatory approval and internal governance.

Deploying an unvalidated clinical AI model carries immense risk: patient harm, regulatory rejection, and catastrophic liability. Our independent validation provides the objective proof you need.

  • Regulatory-Ready Audits: Full performance assessment against real-world datasets to support FDA SaMD and EU MDR submissions.
  • Bias & Fairness Testing: Mathematical analysis for disparate impact across demographic groups to prevent discriminatory outcomes.
  • Robustness & Security: Adversarial testing for data poisoning and model manipulation using frameworks like MITRE ATLAS.

We deliver a comprehensive validation report that serves as your definitive evidence of model safety and efficacy for internal stakeholders and regulators.

DELIVERING REGULATORY CERTAINTY AND CLINICAL SAFETY

Business Outcomes of Rigorous AI Validation

Our independent validation and auditing services provide the evidence and assurance required for safe, effective, and compliant deployment of clinical AI. We focus on measurable outcomes that mitigate risk and accelerate your path to market.

02

Mitigated Clinical Deployment Risk

Our adversarial testing against real-world datasets uncovers performance degradation, bias, and edge-case failures before patient impact. We provide actionable remediation plans to harden your model, ensuring reliability in diverse clinical settings.

>95%
Edge Case Coverage
NIST AI RMF
Risk Framework
04

Robust Operational Monitoring Baseline

Our validation establishes key performance indicators (KPIs) and statistical process control limits for continuous post-market surveillance. This enables proactive drift detection and performance management, a core requirement of the EU AI Act.

Real-time
Drift Detection
EU AI Act
Compliance Ready
05

Strengthened Internal Governance

We deliver clear, auditable documentation of the validation lifecycle—from data provenance to final model performance—creating a single source of truth for your AI governance council. This simplifies internal reviews and investor due diligence.

Full Audit Trail
Documentation
ISO/IEC 42001
Alignment
06

Reduced Long-Term Liability

Independent, third-party validation from our experts provides a defensible layer of due diligence. This documented rigor protects your organization against potential litigation and supports insurance underwriting for AI-based medical devices.

Third-Party
Objective Evidence
MITRE ATLAS
Adversarial Framework
A Phased Approach to Regulatory Readiness

Structured Validation Phases and Deliverables

Our systematic validation process ensures your clinical AI model meets safety, efficacy, and fairness standards for regulatory submission and internal governance. Each phase delivers concrete artifacts to support your compliance journey.

Validation PhaseKey ActivitiesPrimary DeliverablesTypical Timeline

Phase 1: Pre-Validation & Protocol Design

Define validation scope, success criteria, and statistical analysis plan. Select real-world test datasets.

Formal Validation Protocol Document, Statistical Analysis Plan (SAP)

1-2 weeks

Phase 2: Technical Performance Audit

Evaluate model on hold-out test sets. Measure accuracy, sensitivity, specificity, and calibration. Conduct subgroup fairness analysis.

Detailed Performance Report, Fairness & Bias Audit, Confusion Matrices

2-3 weeks

Phase 3: Clinical Utility & Safety Assessment

Simulate clinical workflow integration. Assess impact on clinical decision-making via clinician-in-the-loop testing. Identify failure modes.

Clinical Utility Assessment Report, Failure Mode & Effects Analysis (FMEA)

3-4 weeks

Phase 4: Documentation & Regulatory Packaging

Compile all evidence into a cohesive validation dossier. Prepare documentation for FDA SaMD (if applicable) or internal review boards.

Comprehensive Validation Dossier, Regulatory Submission Package (draft)

2-3 weeks

Ongoing: Post-Market Monitoring Framework

Design continuous monitoring system for model drift, data quality, and real-world performance degradation.

Monitoring Plan, Automated Alerting Dashboard Design

Included in Enterprise

Expert Support & Consultation

Email support during business hours

Priority support with 4-hour SLA

Dedicated technical lead & quarterly reviews

Starting Engagement

From $25K

From $75K

Custom Quote

RIGOROUS INDEPENDENT AUDITING

Validation for Critical Clinical AI Applications

Independent, third-party validation of your clinical AI models against real-world datasets to ensure safety, efficacy, and fairness, supporting regulatory submissions and internal governance.

04

Clinical Safety & Failure Mode Analysis

Systematic identification and risk assessment of potential clinical harm scenarios, including edge cases and adversarial inputs, to build robust safeguards and contingency plans.

05

Explainability & Interpretability Reporting

Generation of clinician-facing model explanations (e.g., saliency maps, feature importance) and technical documentation to build trust and support clinical decision-making.

06

Continuous Monitoring Framework Design

Essential Questions for CTOs and Compliance Leaders

Clinical AI Validation FAQs

Get clear, specific answers on our independent validation and auditing process for clinical AI models, designed to ensure safety, efficacy, and regulatory readiness.

We employ a rigorous, three-phase methodology aligned with FDA SaMD, EU MDR, and ISO/IEC 42001 standards. Phase 1 involves technical performance auditing against real-world datasets to verify accuracy, robustness, and fairness. Phase 2 is a clinical utility assessment, where we evaluate the model's impact on simulated clinical workflows and decision-making. Phase 3 focuses on regulatory documentation, producing the comprehensive validation reports, algorithmic bias assessments, and audit trails required for regulatory submissions. This structured approach has supported successful submissions for 50+ clinical AI projects.

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.